Gerd Burmester Profile Page
| Organisation: | Charité |
| Institute: | Clinic for Rheumatology and Clinical Immunology |
| Address: | Charitéplatz 1 10117 Berlin |
| Campus: | Mitte |
| E-Mail: | This e-mail address is being protected from spam bots, you need JavaScript enabled to view it |
| Field: | Immunotherapy |
| Track(s): | Bio;Med |
| CV: | 2006-present Acting Chairman, Center of Internal Medicine and Dermatology, Charité 1995-1997 Charité University Hospital, Humboldt-University of Berlin, Additional Appointment as Vice Dean 1993-present Charité University Hospital, Humboldt-University of Berlin, Germany Full Professor of Medicine 1990 University of Erlangen-Nuremberg, Professor of Rheumatology and Clinical Immunology 1988 University of Erlangen-Nuremberg, Senior Registrar 1982-1988 Medical School of the University of Erlangen-Nuremberg, Germany Resident (J. R. Kalden) 1980-1982 Rockefeller University, New York, USA, Postdoctoral Fellow (H.G. Kunkel) Hospital for Joint Diseases, Mount Sinai School of Medicine, Visiting Scholar (R.J. Winchester) 1978 Approbation (26. 10.) and MD, Hannover Medical School, Germany 1972 Graduation, Classical Secondary School, Hannover Professional |
| Research Interests: | The focus of Professors Hiepe´s and Burmester’s clinical practice is rheumatoid arthritis, connective tissue disease, Lyme arthritis, and systemic vasculitides. Their research activities include genomics in inflammatory rheumatic diseases (within the National Genome Research Network), new therapeutic approaches for inflammatory and auto-immune diseases, role of memory plasma cells in autoimmunity and allergy, pathogenic and diagnostic relevance of autoantibodies, tissue engineering, regulatory T cells and autoimmunity, and animal models of autoimmunity. This research is carried out in close collaboration with the German Arthritis Research Center(DRFZ) in Berlin. Professors Hiepe and Burmester have participated in many industry-sponsored and investigator initiated clinical trials including studies of biologics such as TNF inhibitors and B cell depleting therapies, and of COX-2 inhibitors and small molecules (Phase I, II, and III). Research projects 1. Development of new autoantibody tests for rheumatoid arthritis 2. Protective versus autoreactive plasma cell memory 3. Regulatory T cells 4. Glucocorticoid receptors and inflammation 5. Gene expression in rheumatoid arthritis 6. Gene expression in SLE 7. New autoantibodies in systemic sclerosis 8. Proteasomes and anti-proteasome antibodies The department provides lectures and practical exercises in rheumatology and clinical immunology. |
| Publications: | Brychcy,M., U.Kuckelkorn, G.Hausdorf, K.Egerer, P.M.Kloetzel, G.R.Burmester, and E.Feist. 2006. Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28. Arthritis Rheum. 54:2175-2183. Hoyer,B.F., K.Moser, A.E.Hauser, A.Peddinghaus, C.Voigt, D.Eilat, A.Radbruch, F.Hiepe, and R.A.Manz. 2004. Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W Mice. J.Exp.Med. 199:1577-1584. Huehn,J., K.Siegmund, J.C.Lehmann, C.Siewert, U.Haubold, M.Feuerer, G.F.Debes, J.Lauber, O.Frey, G.K.Przybylski, U.Niesner, R.M.de la, C.A.Schmidt, R.Brauer, J.Buer, A.Scheffold, and A.Hamann. 2004. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J.Exp.Med. 199:303-313. Pandiyan,P., D.Gartner, O.Soezeri, A.Radbruch, K.Schulze-Osthoff, and M.C.Brunner-Weinzierl. 2004. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J.Exp.Med. 199:831-842. Skriner,K., K.Adolph, P.R.Jungblut, and G.R.Burmester. 2006. Association of citrullinated proteins with synovial exosomes. Arthritis Rheum. 54:3809-3814. |
